Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J McCleary

Showing results (71-80 of 82) with videos related to

Pageof 9
Sort By:
Journal of Geriatric Oncology|February 2, 2022
Age and comorbidity association with survival outcomes in metastatic colorectal cancer: CALGB 80405 analysisNadine J McCleary, Sui Zhang, Chao Ma, et al.
Journal for Immunotherapy of Cancer|June 21, 2023
G-CSF rescue of FOLFIRINOX-induced neutropenia leads to systemic immune suppression in mice and humansVictoire Cardot-Ruffino, Naima Bollenrucher, Luisa Delius, et al.
Journal for Immunotherapy of Cancer|October 1, 2021
Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survivalLeonie K de Klerk, Anuj K Patel, Sarah Derks, et al.
JAMA|April 10, 2019
Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Progression-Free Survival Among Patients With Advanced or Metastatic Colorectal Cancer: The SUNSHINE Randomized Clinical TrialKimmie Ng, Halla S Nimeiri, Nadine J McCleary, et al.
Cancers|November 25, 2020
Effect of High-Dose vs Standard-Dose Vitamin D<sub>3</sub> Supplementation on Body Composition among Patients with Advanced or Metastatic Colorectal Cancer: A Randomized TrialJustin C Brown, Michael H Rosenthal, Chao Ma, et al.
JNCI Cancer Spectrum|May 23, 2022
Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical TrialsNadine J McCleary, William S Harmsen, Ellana Haakenstad, et al.
Journal for Immunotherapy of Cancer|January 25, 2024
Biomarkers of pembrolizumab efficacy in advanced anal squamous cell carcinoma: analysis of a phase II clinical trial and a cohort of long-term respondersBrandon M Huffman, Harshabad Singh, Lestat R Ali, et al.
Cancer Immunology Research|July 11, 2024
Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the TumorPaul E Oberstein, Andressa Dias Costa, Emily A Kawaler, et al.
JCO Precision Oncology|September 2, 2025
Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreatic CancerRishi Surana, Micaela Morgado, Ashwin Somasundaram, et al.
JCO Precision Oncology|January 12, 2023
Programmatic Precision Oncology Decision Support for Patients With Gastrointestinal CancerRachel B Keller, Tali Mazor, Lynette Sholl, et al.
Pageof 9

Showing results (71-80 of 82) with videos related to

Sort By:
Pageof 9
Journal of Geriatric Oncology|February 2, 2022
Age and comorbidity association with survival outcomes in metastatic colorectal cancer: CALGB 80405 analysisNadine J McCleary, Sui Zhang, Chao Ma, et al.
Journal for Immunotherapy of Cancer|June 21, 2023
G-CSF rescue of FOLFIRINOX-induced neutropenia leads to systemic immune suppression in mice and humansVictoire Cardot-Ruffino, Naima Bollenrucher, Luisa Delius, et al.
Journal for Immunotherapy of Cancer|October 1, 2021
Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survivalLeonie K de Klerk, Anuj K Patel, Sarah Derks, et al.
JAMA|April 10, 2019
Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Progression-Free Survival Among Patients With Advanced or Metastatic Colorectal Cancer: The SUNSHINE Randomized Clinical TrialKimmie Ng, Halla S Nimeiri, Nadine J McCleary, et al.
Cancers|November 25, 2020
Effect of High-Dose vs Standard-Dose Vitamin D<sub>3</sub> Supplementation on Body Composition among Patients with Advanced or Metastatic Colorectal Cancer: A Randomized TrialJustin C Brown, Michael H Rosenthal, Chao Ma, et al.
JNCI Cancer Spectrum|May 23, 2022
Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical TrialsNadine J McCleary, William S Harmsen, Ellana Haakenstad, et al.
Journal for Immunotherapy of Cancer|January 25, 2024
Biomarkers of pembrolizumab efficacy in advanced anal squamous cell carcinoma: analysis of a phase II clinical trial and a cohort of long-term respondersBrandon M Huffman, Harshabad Singh, Lestat R Ali, et al.
Cancer Immunology Research|July 11, 2024
Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the TumorPaul E Oberstein, Andressa Dias Costa, Emily A Kawaler, et al.
JCO Precision Oncology|September 2, 2025
Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreatic CancerRishi Surana, Micaela Morgado, Ashwin Somasundaram, et al.
JCO Precision Oncology|January 12, 2023
Programmatic Precision Oncology Decision Support for Patients With Gastrointestinal CancerRachel B Keller, Tali Mazor, Lynette Sholl, et al.
Pageof 9